Disappointingly, even though rosiglitazone substantially improved steatosis in the first year, longer treatment did not improve NASH histology despite maintained effects on insulin sensitivity and ALT levels [110]. Here, INS is linked to metabolic dysfunction-associated steatohepatitis.